Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

NCT ID: NCT06146972

Last Updated: 2024-03-25

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 117 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2024-05-31

Brief Summary

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease with predominantly joint involvement. To compare the efficacy and difference between elamod and tofacitib in the treatment of rheumatoid factor-positive and negative rheumatoid arthritis in RA patients with poor outcome after csDMARDs dosing, in order to better inform the clinical management.

Detailed Description

This is an open, controlled, interventional clinical study enrolling patients with active RA who meet the following entry row criteria, and treating patients with IGU 25 mg bid + tofacitinib 5 mg bid for the intervention. The screening period was defined as the screening visit was conducted within 1 month prior to the baseline visit, and efficacy and safety assessments were performed at time points 0, 4, 12, 18, and 24 weeks from the time the subject was treated with the study protocol (see efficacy and safety endpoints for details), and study subjects were asked to come to the hospital for follow-up within ±3 days of the corresponding follow-up point.

Conditions

Rheumatoid Arthritis; Therapy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RF positive group

Iguratimod (25mg per tablet) 25mg twice daily plus tofacitinib (5mg per tablet) 5mg twice daily for 24 weeks.

Group Type: EXPERIMENTAL

Iguratimod

Intervention Type: DRUG

Iguratimod 25mg bid + tofacitinib 5mg bid

RF negative group

Iguratimod (25mg per tablet) 25mg twice daily plus tofacitinib (5mg per tablet) 5mg twice daily for 24 weeks.

Group Type: EXPERIMENTAL

Iguratimod

Intervention Type: DRUG

Iguratimod 25mg bid + tofacitinib 5mg bid

Interventions

Iguratimod

Iguratimod 25mg bid + tofacitinib 5mg bid

Intervention Type: DRUG

Other Intervention Names

tofacitinib

Eligibility Criteria

Inclusion Criteria

1. Male or female aged 18-65 years old

2. Body weight not less than 40kg

3. Patients with a clear diagnosis of rheumatoid arthritis (RA) who meet the diagnostic criteria for RA introduced by the ACR in 1987 or ACR\EULAR in 2010

4. Joint function grade II-III

5. Active rheumatoid arthritis (defined as active rheumatoid arthritis if the following three conditions are met: ① ≥ 6 joints swollen [66 joints count]

② ≥ 6 joints tenderness [68 joints count]

③Erythrocyte sedimentation rate (ESR) > 28 mm/h or C-reactive protein (CRP) > 1.0 mg/dL)

6. The Patients have been treated with csDMARDs for ≥ 3 months and have been treated with stable doses of csDMARDs for 4 consecutive weeks prior to study entry, with poor therapeutic outcomes and are being considered for treatment with a combination of biologics (bDMARDs) (according to the 2018 China Rheumatoid Arthritis Treatment Guidelines, poor outcomes, i.e., no significant improvement in RA disease activity within 3 months or failure to achieve treatment goals within 6 months)

7. Subjects must be able and willing to perform subcutaneous (SC) injections on their own, or a qualified person must be available to perform SC injections

8. If taking glucocorticosteroids, prednisone should be ≤10mg or other hormone at a dose equivalent to prednisone and the dose should be kept constant for at least 28d

9. Understand the purpose of the trial and the test procedures and sign a written informed consent form voluntarily

Exclusion Criteria

1. Patients who have used potent immunosuppressants (such as cyclophosphamide, cyclosporine, azathioprine, etc.), tripterygiam glycosides and so on that affect the evaluation of efficacy in previous rheumatoid arthritis treatment , and who have stopped taking them for less than 4 weeks

2. History of allergy to relevant test drugs

3. Previously treated with bDMARDs

4. Subject has recently received a live vaccine, or plans to use any live vaccine during the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yanfeng Hou

OTHER

Sponsor Role: lead

Responsible Party

Yanfeng Hou

professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Yanfeng Hou, Dr.

Role: STUDY_DIRECTOR

Yanfeng Hou

Locations

Yanfeng Hou

Jinan, Shandong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Yanfeng Hou, Dr.

Role: CONTACT

yfhou1016@163.com

15168888165

Facility Contacts

Yanfeng Hou

Role: primary

yfhou1016@163.com

15168888165

Other Identifiers

GZPK2021Z0629

Identifier Type: -

Identifier Source: org_study_id